Skip to main content
SpringerLink
Log in

Endothelin Receptor Antagonists and Acute Heart Failure Syndromes

  • Chapter
Acute Heart Failure

Abstract

As noted in the preceding chapters, the acute heart failure syndrome (AHFS) has been largely ignored until recently, despite its role as the primary hospital discharge diagnosis in 1million patients per year and accounting for over $14 billion in hospital costs in the United States alone.1 The therapeutic approach to these patients has remained essentially unchanged for decades, despite, or perhaps due to, the relative absence of clinical trial evidence. Recent surveys have demonstrated that with current therapy, patients admitted for AHFS have a 45% chance of readmission2 and a 20% to 40% risk of death in the following 6 months. Given these poor outcomes, the medical community is reevaluating the current therapeutic approach and searching for new therapies to treat patients with AHFS. One result of this reassessment of acute heart failure (AHF) has been the recognition of AHF as a vascular disorder and the need to develop therapies that can provide vascular protection. Endothelin receptor antagonists provide a potential novel approach to the treatment of AHF by addressing the underlying pathophysiologic abnormalities in this syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. American Heart Association. Heart Disease and Stroke Statistics—2004 Update. Dallas, TX: American Heart Association; 2003.

    Google Scholar 

  2. Krumholz HM, Parent EM, Tu N, et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Intern Med. 1997;157(1):99–104.

    Article  CAS  PubMed  Google Scholar 

  3. Dikshit K, Vyden JK, Forrester JS, Chatterjee K, Prakash R, Swan HJ. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med. 1973;288(21):1087–90.

    Article  CAS  PubMed  Google Scholar 

  4. The ADHERE® Registry. Second Quarter 2003 National Benchmark Report. http://www.adhereregistry.com/national_BMR/Q2_03_National_ADHERE_BMR.pdf. Scios, Inc. Available at: http://www.adhereregistry.com/national_BMR/Q2_03_National_ADHERE_BMR.pdf.

    Google Scholar 

  5. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411–5.

    Article  CAS  PubMed  Google Scholar 

  6. Cernacek P, Stewart DJ. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem Biophys Res Commun. 1989;161(2):562–7.

    Article  CAS  PubMed  Google Scholar 

  7. Margulies KB, Hildebrand FL Jr, Lerman A, Perrella MA, Burnett JC Jr. Increased endothelin in experimental heart failure. Circulation. 1990;82(6):2226–30.

    CAS  PubMed  Google Scholar 

  8. Teerlink JR, Löffler BM, Hess P, Maire JP, Clozel M, Clozel JP. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation. 1994;90(5):2510–8.

    CAS  PubMed  Google Scholar 

  9. Aronson D, Burger AJ. Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: role of endothelin. Pacing Clin Electrophysiol. 2003;26(3):703–10.

    Article  PubMed  Google Scholar 

  10. Aronson D, Burger AJ. Neurohormonal prediction of mortality following admission for decompensated heart failure. Am J Cardiol. 2003;91(2):245–8.

    Article  CAS  PubMed  Google Scholar 

  11. McNeill JR. Role of endothelin in regulation of resistance, fluid-exchange, and capacitance functions of the systemic circulation. Can J Physiol Pharmacol. 2003;81(6):522–32.

    Article  CAS  PubMed  Google Scholar 

  12. Gray GA, Löffler BM, Clozel M. Characterization of endothelin receptors mediating contraction of rabbit saphenous vein. Am J Physiol. 1994;266(3 pt 2):H959–H66.

    CAS  PubMed  Google Scholar 

  13. Teerlink JR, Breu V, Sprecher U, Clozel M, Clozel JP. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res. 1994;74(1):105–14.

    CAS  PubMed  Google Scholar 

  14. Dohi Y, Hahn AW, Boulanger CM, Buhler FR, Luscher TF. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension. 1992;19(2):131–7.

    CAS  PubMed  Google Scholar 

  15. Clozel M, Clozel JP. Effects of endothelin on regional blood flows in squirrel monkeys. J Pharmacol Exp Ther. 1989;250(3):1125–31.

    CAS  PubMed  Google Scholar 

  16. Ekelund U, Albert U, Edvinsson L, Mellander S. In-vivo effects of endothelin-1 and ETA receptor blockade on arterial, venous and capillary functions in skeletal muscle. Acta Physiol Scand. 1993;148(3):273–83.

    Article  CAS  PubMed  Google Scholar 

  17. Ekelund U, Adner M, Edvinsson L, Mellander S. Effects of selective ETB-receptor stimulation on arterial, venous and capillary functions in cat skeletal muscle. Br J Pharmacol. 1994;112(3):887–94.

    CAS  PubMed  Google Scholar 

  18. Filep JG, Fournier A, Foldes-Filep E. Acute proinflammatory actions of endothelin-1 in the guineapig lung: involvement of ETA and ETB receptors. Br J Pharmacol. 1995;115(2):227–36.

    CAS  PubMed  Google Scholar 

  19. Hocher B, Thone-Reineke C, Rohmeiss P, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest. 1997;99(6):1380–9.

    Article  CAS  PubMed  Google Scholar 

  20. Moreau P, Dao HH. Endothelin receptor antagonists: novel agents for the treatment of hypertension? Expert Opin Invest Drugs. 1999;8(11):1807–21.

    Article  Google Scholar 

  21. Schiffrin EL. Role of endothelin-1 in hypertension and vascular disease. Am J Hypertens. 2001;14(6 pt 2):83S–9S.

    Article  CAS  PubMed  Google Scholar 

  22. Dao HH, Martens FM, Lariviere R, Yamaguchi N, Cernacek P, de Champlain J, Moreau P. Transient involvement of endothelin in hypertrophic remodeling of small arteries. J Hypertens. 2001;19(10):1801–12.

    Article  CAS  PubMed  Google Scholar 

  23. Loennechen JP, St<o/>ylen A, Beisvag V, Wisl<o/>ff U, Ellingsen O. Regional expression of endothelin-1, ANP, IGF-1, and LV wall stress in the infarcted rat heart. Am J Physiol Heart Circ Physiol. 2001;280(6):H2902–H10.

    CAS  PubMed  Google Scholar 

  24. Tsutamoto T, Wada A, Maeda K, et al. Transcardiac extraction of circulating endothelin-1 across the failing heart. Am J Cardiol. 2000;86(5):524–8.

    Article  CAS  PubMed  Google Scholar 

  25. Yamamoto T, Kimura T, Ota K, et al. Central effects of endothelin-1 on vasopressin release, blood pressure, and renal solute excretion. Am J Physiol. 1992;262(6 pt 1):E856–E62.

    CAS  PubMed  Google Scholar 

  26. Belloni AS, Rossi GP, Andreis PG, et al. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension. 1996;27(5):1153–9.

    CAS  PubMed  Google Scholar 

  27. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992;19(6 pt 2):753–7.

    CAS  PubMed  Google Scholar 

  28. Yoshida K, Yasujima M, Kohzuki M, Kanazawa M, Yoshinaga K, Abe K. Endothelin-1 augments pressor response to angiotensin II infusion in rats. Hypertension. 1992;20(3):292–7.

    CAS  PubMed  Google Scholar 

  29. Kaddoura S, Firth JD, Boheler KR, Sugden PH, Poole-Wilson PA. Endothelin-1 is involved in norepinephrine-induced ventricular hypertrophy in vivo. Acute effects of bosentan, an orally active, mixed endothelin ETA and ETB receptor antagonist. Circulation. 1996;93(11):2068–79.

    CAS  PubMed  Google Scholar 

  30. MacCarthy PA, Grocott-Mason R, Prendergast BD, Shah AM. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation. 2000;101(2):142–7.

    CAS  PubMed  Google Scholar 

  31. Duru F, Barton M, Lüscher TF, Candinas R. Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs? Cardiovasc Res. 2001;49(2):272–80.

    Article  CAS  PubMed  Google Scholar 

  32. Yorikane R, Shiga H, Miyake S, Koike H. Evidence for direct arrhythmogenic action of endothelin. Biochem Biophys Res Commun. 1990;173(1):457–62.

    Article  CAS  PubMed  Google Scholar 

  33. Burrell KM, Molenaar P, Dawson PJ, Kaumann AJ. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J Pharmacol Exp Ther. 2000;292(1):449–59.

    CAS  PubMed  Google Scholar 

  34. Rabelink TJ, Kaasjager KA, Boer P, Stroes EG, Braam B, Koomans HA. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int. 1994;46(2):376–81.

    Article  CAS  PubMed  Google Scholar 

  35. Sorensen SS, Madsen JK, Pedersen EB. Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am J Physiol. 1994;266(3 Pt 2):F411–F8.

    CAS  PubMed  Google Scholar 

  36. Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens. 2004;13(2):163–70.

    Article  CAS  PubMed  Google Scholar 

  37. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35(3):681–9.

    Article  CAS  PubMed  Google Scholar 

  38. Hess P, Clozel M, Clozel JP. Telemetry monitoring of pulmonary arterial pressure in freely moving rats. J Appl Physiol. 1996;81(2):1027–32.

    CAS  PubMed  Google Scholar 

  39. Clozel M, Qiu C, Qiu CS, Hess P, Clozel JP. Shortterm endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction. J Am Coll Cardiol. 2002;39(1):142–7.

    Article  CAS  PubMed  Google Scholar 

  40. Filep JG. Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade. Hypertension. 1997;30(1 Pt 1):22–8.

    CAS  PubMed  Google Scholar 

  41. Finsnes F, Skjonsberg OH, Tonnessen T, Naess O, Lyberg T, Christensen G. Endothelin production and effects of endothelin antagonism during experimental airway inflammation. Am J Respir Crit Care Med. 1997;155(4):1404–12.

    CAS  PubMed  Google Scholar 

  42. Verma S, Li SH, Badiwala MV, Weisel RD, Fedak PW, Li RK, Dhillon B, Mickle DA. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation. 2002;105(16):1890–6.

    Article  CAS  PubMed  Google Scholar 

  43. Lariviere R, Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol. 2003;81(6):607–21.

    Article  CAS  PubMed  Google Scholar 

  44. Hino A, Weir BK, Macdonald RL, Thisted RA, Kim CJ, Johns LM. Prospective, randomized, doubleblind trial of BQ-123 and bosentan for prevention of vasospasm following subarachnoid hemorrhage in monkeys. J Neurosurg. 1995;83(3):503–9.

    Article  CAS  PubMed  Google Scholar 

  45. Kwan AL, Lin CL, Chang CZ, et al. Oral administration of an inhibitor of endothelin-converting enzyme attenuates cerebral vasospasm following experimental subarachnoid haemorrhage in rabbits. Clin Sci (Lond). 2002;103:414S–7S.

    CAS  Google Scholar 

  46. Ohnishi M, Wada A, Tsutamoto T, et al. Chronic effects of a novel, orally active endothelin receptor antagonist, T-0201, in dogs with congestive heart failure. J Cardiovasc Pharmacol. 1998;31(2):S236–S8.

    Article  CAS  PubMed  Google Scholar 

  47. Bauersachs J, Braun C, Fraccarollo D, et al. Improvement of renal dysfunction in rats with chronic heart failure after myocardial infarction by treatment with the endothelin A receptor antagonist, LU 135252. J Hypertens. 2000;18(10):1507–14.

    Article  CAS  PubMed  Google Scholar 

  48. Qiu C, Ding SS, Hess P, Clozel JP, Clozel M. Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure. J Cardiovasc Pharmacol. 2001;38(2):317–24.

    Article  CAS  PubMed  Google Scholar 

  49. Ding SS, Qiu C, Hess P, Xi JF, Clozel JP, Clozel M. Chronic endothelin receptor blockade prevents renal vasoconstriction and sodium retention in rats with chronic heart failure. Cardiovasc Res. 2002;53(4):963–70.

    Article  CAS  PubMed  Google Scholar 

  50. Fleisch M, Sutsch G, Yan XW, et al. Systemic, pulmonary, and renal hemodynamic effects of endothelin ET(A/B)-receptor blockade in patients with maintained left ventricular function. J Cardiovasc Pharmacol. 2000;36(3):302–9.

    Article  CAS  PubMed  Google Scholar 

  51. Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res. 1993;27(9):1613–18.

    Article  CAS  PubMed  Google Scholar 

  52. Burke SE, Nelson RA. Endothelin-receptor antagonist FR 139317 reduces infarct size in a rabbit model when given before, but not after, coronary artery occlusion. J Cardiovasc Pharmacol. 1997;29(1):87–92.

    Article  CAS  PubMed  Google Scholar 

  53. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384(6607):353–5.

    Article  CAS  PubMed  Google Scholar 

  54. Mulder P, Richard V, Bouchart F, Derumeaux G, Münter K, Thuillez C. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Cardiovasc Res. 1998;39(3):600–8.

    Article  CAS  PubMed  Google Scholar 

  55. Podesser BK, Siwik DA, Eberli FR, et al. ET(A)-receptor blockade prevents matrix metalloproteinase activation late postmyocardial infarction in the rat. Am J Physiol Heart Circ Physiol. 2001;280(3):H984–H91.

    CAS  PubMed  Google Scholar 

  56. Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Beneficial effects on left ventricular and myocyte function. Circulation. 1997;95(7):1918–29.

    CAS  PubMed  Google Scholar 

  57. Nguyen QT, Cernacek P, Calderoni A, et al. Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation. 1998;98(21):2323–30.

    CAS  PubMed  Google Scholar 

  58. Hu K, Gaudron P, Schmidt TJ, Hoffmann KD, Ertl G. Aggravation of left ventricular remodeling by a novel specific endothelin ET(A) antagonist EMD94246 in rats with experimental myocardial infarction. J Cardiovasc Pharmacol. 1998;32(3):505–8.

    Article  CAS  PubMed  Google Scholar 

  59. Moe GW, Albernaz A, Naik GO, Kirchengast M, Stewart DJ. Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure. Cardiovasc Res. 1998;39(3):571–9.

    Article  CAS  PubMed  Google Scholar 

  60. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther. 1994;270(1):228–35.

    CAS  PubMed  Google Scholar 

  61. Mulder P, Richard V, Derumeaux G, et al. Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling. Circulation. 1997;96(6):1976–82.

    CAS  PubMed  Google Scholar 

  62. Fraccarollo D, Hu K, Galuppo P, Gaudron P, Ertl G. Chronic endothelin receptor blockade attenuates progressive ventricular dilation and improves cardiac function in rats with myocardial infarction: possible involvement of myocardial endothelin system in ventricular remodeling. Circulation. 1997;96(11):3963–73.

    CAS  PubMed  Google Scholar 

  63. Oie E, Bjonerheim R, Grogaard HK, Kongshaug H, Smiseth OA, Attramadal H. ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats. Am J Physiol Heart Circ Physiol. 1998;275(3 pt 2):H868–H77.

    CAS  Google Scholar 

  64. Iwanaga Y, Kihara Y, Inagaki K, et al. Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure. Circulation. 2001;104(5):606–12.

    Article  CAS  PubMed  Google Scholar 

  65. Mishima T, Tanimura M, Suzuki G, et al. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure. J Am Coll Cardiol. 2000;35(1):222–9.

    Article  CAS  PubMed  Google Scholar 

  66. Clozel M, Ramuz H, Clozel JP, et al. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use. J Pharmacol Exp Ther. 1999;290(2):840–6.

    CAS  PubMed  Google Scholar 

  67. Qiu CB, Qiu CS, Hess P, Clozel JP, Clozel M. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure. Acta Pharmacol Sin. 2001;22(6):541–8.

    CAS  PubMed  Google Scholar 

  68. Seed A, Love MP, McMurray JJ. Clinical experience with endothelin receptor antagonists in chronic heart failure. Heart Fail Rev. 2001;6(4):317–23.

    Article  CAS  PubMed  Google Scholar 

  69. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;346(8977):732–6.

    Article  CAS  PubMed  Google Scholar 

  70. Sütsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation. 1998;98(21):2262–8.

    PubMed  Google Scholar 

  71. Dingemanse J, Clozel M, van Giersbergen PL. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects. Br J Clin Pharmacol. 2002;53(4):355–62.

    Article  CAS  PubMed  Google Scholar 

  72. van Giersbergen PL, Dingemanse J. Effect of severe renal impairment on the pharmacokinetics and tolerability of the parenteral endothelin antagonist tezosentan. Int J Clin Pharmacol Ther. 2003;41(6):261–6.

    PubMed  Google Scholar 

  73. Schalcher C, Cotter G, Reisin L, et al. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. Am Heart J. 2001;142(2):340–9.

    Article  CAS  PubMed  Google Scholar 

  74. Torre-Amione G, Young JB, Durand J, et al. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. Circulation. 2001;103(7):973–80.

    CAS  PubMed  Google Scholar 

  75. Torre-Amione G, Durand JB, Nagueh S, Vooletich MT, Kobrin I, Pratt C. A pilot safety trial of prolonged (48 h) infusion of the dual endothelinreceptor antagonist tezosentan in patients with advanced heart failure. Chest. 2001;120(2):460–6.

    Article  CAS  PubMed  Google Scholar 

  76. Cowburn PJ, Cleland JG, McArthur JD, MacLean MR, McMurray JJ, Dargie HJ. Short-term haemodynamic effects of BQ-123, a selective endothelin ET(A)-receptor antagonist, in chronic heart failure. Lancet. 1998;352(9123):201–02.

    Article  CAS  PubMed  Google Scholar 

  77. Spieker LE, Mitrovic V, Noll G, et al. Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol. 2000;35(7):1745–52.

    Article  CAS  PubMed  Google Scholar 

  78. Lüscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation. 2002;106(21):2666–72.

    Article  PubMed  CAS  Google Scholar 

  79. Givertz MM, Colucci WS, LeJemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation. 2000;101(25):2922–7.

    CAS  PubMed  Google Scholar 

  80. Ooi H, Colucci WS, Givertz MM. Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Circulation. 2002;106(13):1618–21.

    Article  CAS  PubMed  Google Scholar 

  81. Smith W, Iteld B, LeJemtel T, et al. Improved hemodynamics with the ETA selective receptor antagonist BMS-193884 in patients with heart failure. J Am Coll Cardiol. 2000;35(2):241 (Abstract).

    Google Scholar 

  82. Chen HH, Salz LM, McKinley LJ, et al. Safety and efficacy of an orally active selective endothelin-A receptor antagonist in moderate-severe human chronic heart failure. J Cardiac Fail. 1999;5(3):172 (astr).

    Google Scholar 

  83. Cotter G, Kiowski W, Kaluski E, et al. Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure. Eur J Heart Fail. 2001;3(4):457–61.

    Article  CAS  PubMed  Google Scholar 

  84. Teerlink JR, Torre-Amione G. A new strategy for a clinical development program in acute decompensated heart failure: The Randomized Intravenous TeZosentan (RTIZ) trials. J Cardiac Fail. 2000;6(suppl 2):48 (abstr).

    Google Scholar 

  85. Torre-Amione G, Young JB, Colucci WS, et al. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2003;42(1):140–7.

    Article  CAS  PubMed  Google Scholar 

  86. Teerlink JR, Massie BM, Cleland JGF, Tzivoni D, for the RITZ-1 Investigators. A double-blind, parallelgroup, multi-center, placebo-controlled study to investigate the efficacy and safety of tezosentan in reducing symptoms in patients with acute decompensated heart failure. Circulation. 2001;104:II-526 (abstr).

    Google Scholar 

  87. Coletta AP, Cleland JG. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology-WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail. 2001;3(6):747–50.

    Article  CAS  PubMed  Google Scholar 

  88. O’Connor CM, Gattis WA, Adams KF Jr, et al. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). J Am Coll Cardiol. 2003;41(9):1452–7.

    Article  PubMed  CAS  Google Scholar 

  89. Kaluski E, Kobrin I, Zimlichman R, et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol. 2003;41(2):204–10.

    Article  CAS  PubMed  Google Scholar 

  90. Cotter G, Kaluski E, Stangl K, et al. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail. 2004;6(5):601–9.

    Article  CAS  PubMed  Google Scholar 

  91. Teerlink JR, McMurray JJ, Bourge RC, et al. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J. 2005;150(1):46–53.

    Article  CAS  PubMed  Google Scholar 

  92. McMurray JJ, Teerlink JR. Late-breaking clinical trials session: Value of Endothelin Receptor Inhibition With Tezosentan in Acute Heart Failure Studies (VERITAS). Paper presented at the American College of Cardiology Annual Scientific Session March 9, 2005, Orlando, FL.

    Google Scholar 

  93. Teerlink JR. Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure. Am Heart J. 2003;145(2 suppl):S26–33.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA, USA

    John R. Teerlink MD, FACC, FAHA, FESC

Authors
  1. John R. Teerlink MD, FACC, FAHA, FESC
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Anesthesiology and Critical Care Medicine, Lariboisière University Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France

    Alexandre Mebazaa MD, PhD (Professor of Medicine) (Professor of Medicine)

  2. Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

    Mihai Gheorghiade MD, FACC (Professor of Medicine and Surgery, Associate Chief, Division of Cardiology and Chief, Cardiology Clinical Service) (Professor of Medicine and Surgery, Associate Chief, Division of Cardiology and Chief, Cardiology Clinical Service)

  3. Department of Cardiology Centre d’Investigation Clinique (CIC), INSERM U-684, Centre Hospitalier Universitaire, University Henri Poincaré, Nancy, France

    Faiez M. Zannad MD, PhD, FESC (Professor of Medicine) (Professor of Medicine)

  4. Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Camden, NJ, USA

    Joseph E. Parrillo MD (Professor of Medicine, Chief, Department of Medicine Edward D. Viner MD Chair, Department of Medicine and Director) (Professor of Medicine, Chief, Department of Medicine Edward D. Viner MD Chair, Department of Medicine and Director)

  5. Cooper Heart Institute, Cooper University Hospital, Camden, NJ, USA

    Joseph E. Parrillo MD (Professor of Medicine, Chief, Department of Medicine Edward D. Viner MD Chair, Department of Medicine and Director) (Professor of Medicine, Chief, Department of Medicine Edward D. Viner MD Chair, Department of Medicine and Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Teerlink, J.R. (2008). Endothelin Receptor Antagonists and Acute Heart Failure Syndromes. In: Mebazaa, A., Gheorghiade, M., Zannad, F.M., Parrillo, J.E. (eds) Acute Heart Failure. Springer, London. https://doi.org/10.1007/978-1-84628-782-4_58

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-782-4_58

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-781-7

  • Online ISBN: 978-1-84628-782-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation